“GLP-1 receptor agonist use was not associated with an increased risk of suicidal ideation, self-harm, or suicide” compared ...
12h
Hosted on MSNOn the rebound: What are the long-term risks of Ozempic?Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...
Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
It’s normal to have lots of questions when you start a new prescription medication. Whether you can drink alcohol might be at ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This ...
“As time goes on, they’re more willing to share their story because they get so many compliments,” she said. “The person who is next to them says, ‘Tell me your secret,’ and they may whisper my name ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results